Staff Profile
Huw Thomas
Senior Research Associate
- Email: huw.thomas@ncl.ac.uk
- Telephone: +44 (0) 191 208 4300
- Address: University of Newcastle Upon Tyne
Translational and Clinical Research Institute
Paul O'Gorman Building
Medical School
Framlington Place
Newcastle upon Tyne
NE2 4HH
Qualifications
BSc (hons) Pharmacology 1991
MPhil 1999
Previous Positions
Research Technician 1993-1996
Junior Research associate 1996-2000
Memberships
BACR
PAMM
Research Interests
Pharmacology of novel drugs to treat cancer
Pharmacokinetics
Other Expertise
Analysis of drugs in biological material
Current Work
Evaluation of, novel drugs to inhibit DNA repair-mediated resistance to anticancer therapy, CDK inhibitors and novel nucleoside transport inhibitors to enhance antifolate efficacy.
Postgraduate Supervision
MRes student supervision 2004
Funding
Preclinical and pharmacodynamic studies with Novel DNA-PK inhibitors. N.J. Curtin (PI, 40%) A.H. Calvert (5%), BW Durkacz (10%), BT Golding (5%), RJ Griffin (5%), IR Hardcastle (5%), D.R. Newell (20%), H. Thomas (10%). KuDos Pharmaceuticals 06/02-05/06 £355,171
Preclinical evaluation of DNA-PK and ATM inhibitors. N.J. Curtin (PI, 40%) A.H. Calvert (5%), BW Durkacz (10%), BT Golding (5%), RJ Griffin (5%), IR Hardcastle (5%), D.R. Newell (20%), H. Thomas (10%). KuDos Pharmaceuticals 01/03-12/06 £413,088
Preclinical Evaluation of AT5438 D.R. Newell (PI = 50%) N.J. Curtin (25%), H. Thomas (25%). Astex Technology Ltd 05/03-05/04 £15,253
- Bainbridge A, Walker S, Smith J, Patterson K, Dutt D, Ng YM, Thomas HD, Wilson L, McCullough B, Jones D, Maan A, Banks P, McCracken SRC, Gaughan L, Robson CN, Coffey K. IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway. Nucleic Acids Research 2020, 48(10), 5366-5382.